New York Post July 6, 2024
“Rich people get Ozempic. Poor people get body positivity.”
That was one of the iconic lines from a “South Park” special in May dubbed “The End of Obesity.”
The show focused its trademark satire on semaglutide, a class of type-2 diabetes drugs that have become popular in the last few years, particularly among wealthier Americans, for weight loss.
But why the class dichotomy?
America’s obesity problem is expensive, in ways we don’t even think about.
We should rethink the idea that semaglutide — and its name brands such as Ozempic and Wegovy —should be available only to the rich who can afford them.
What if we could actually save money in the long run by making such drugs accessible to...
Today's Sponsors
Today's Sponsor